The Hidden Risks of BPC157: What Patients Need to Know About Contamination and Safety Regenexx at New Regeneration Orthopedics In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for FDA to Review 7 Peptides for Compounding List in July 2026: BPC 157, Semax, Epitalon, and More HealingMaps The FDA has issued clear signals on BPC 157: it is not approved for human use in any form due to potential significant safety risks. This critical classification profoundly impacts research and Why Are People Injecting Themselves with Peptides? The New Yorker